PMN-MDSCs are pathologically activated neutrophils that accumulate in many diseases. These cells are vital for the regulation of immune responses in cancer, the promotion of tumour progression, and metastases, and their presence correlates with poor prognosis and negative responses to immunotherapy [1] [2] [3] [4] . Despite the fact that neutrophils and PMN-MDSCs share the same origin and differentiation pathways, PMN-MDSCs have distinct genomic and biochemical features and are immunosuppressive 2 . The mechanisms responsible for the pathological activation of neutrophils are not well defined, thus limiting the selective targeting of these cells. We asked whether changes in lipid metabolism could contribute to the pathological activation of PMN-MDSCs. An accumulation of lipids in cancer has been shown in macrophages [5] [6] [7] , dendritic cells [8] [9] [10] [11] , and a population of mouse MDSCs where it was associated with suppressive activity 12 . Here we report a specific role of FATP2 in the regulation of PMN-MDSC function.
PMN-MDSCs are pathologically activated neutrophils that accumulate in many diseases. These cells are vital for the regulation of immune responses in cancer, the promotion of tumour progression, and metastases, and their presence correlates with poor prognosis and negative responses to immunotherapy [1] [2] [3] [4] . Despite the fact that neutrophils and PMN-MDSCs share the same origin and differentiation pathways, PMN-MDSCs have distinct genomic and biochemical features and are immunosuppressive 2 . The mechanisms responsible for the pathological activation of neutrophils are not well defined, thus limiting the selective targeting of these cells. We asked whether changes in lipid metabolism could contribute to the pathological activation of PMN-MDSCs. An accumulation of lipids in cancer has been shown in macrophages [5] [6] [7] , dendritic cells [8] [9] [10] [11] , and a population of mouse MDSCs where it was associated with suppressive activity 12 . Here we report a specific role of FATP2 in the regulation of PMN-MDSC function.
FATP2 controls the suppressive activity of PMN-MDSCs
We evaluated total lipid levels in CD11b
Ly6G
+ PMN-MDSCs from the spleens of tumour-bearing mice and in polymorphonuclear neutrophils (PMNs) with the same phenotype from the spleens of tumour-free mice in transplantable models of EL4 lymphoma, Lewis lung carcinoma (LLC), and CT26 colon carcinoma, as well as in a genetically engineered model of pancreatic cancer (KPC). PMNMDSCs in all tested models showed substantially higher amounts of lipids than control PMNs (Extended Data Fig. 1a ). Tumour explant supernatant promoted the accumulation of lipids in PMNs differentiated in vitro from bone marrow haematopoietic progenitor cells (HPCs) (Extended Data Fig. 1b) . Liquid chromatography-mass spectrometry (LC-MS) lipidomics analysis of triglycerides-the major component of lipid droplets 13 -revealed that PMN-MDSCs from the spleen of tumour-bearing mice had significantly more triglycerides than PMNs from control mice (Extended Data Fig. 1c ). This effect was particularly robust (approximately eightfold) in triglycerides that contain arachidonic acid (AA). A similar analysis was performed in CD11b + Ly6C high Ly6G − monocytic MDSCs (M-MDSCs) from tumour-bearing mice and in monocytes with the same phenotype from tumour-free mice. In all tested models, M-MDSCs had markedly increased accumulation of lipids (Extended Data Fig. 1d ).
Previous studies demonstrated that lipid accumulation in dendritic cells was mediated by the upregulation of the scavenger receptor CD204 [8] [9] [10] . However, whereas the accumulation of lipids was abrogated in CD204-deficient (Msr1 −/− ) dendritic cells, it was not affected in PMNs (Extended Data Fig. 1e ). These results were confirmed in vivo using bone marrow chimaeras of Msr1 −/− and wild-type mice. A lack of CD204 did not abrogate lipid uptake by PMN-MDSCs (Extended Data Fig. 1f ) and did not cancel their suppressive activity (Extended Data Fig. 1g ). Several membrane proteins have been implicated in the trafficking of lipids, including CD206, CD36, fatty acid-binding proteins (FABPs) and fatty acid transport proteins (FATPs; also known as solute carrier 27, SLC27). The FATP family includes six members (FATP1-FATP6). FATP acts as a long-chain fatty acid transporter and an acyl-coenzyme A (CoA) synthetase [14] [15] [16] . Acyl-CoA synthetase converts free long-chain fatty acids into fatty acyl-CoA esters, which can be used in many metabolic processes, including the synthesis Article reSeArcH and oxidation of fatty acids, and the synthesis of complex lipids. We compared the expression of genes potentially involved in lipid uptake between PMN-MDSCs from EL4 tumour-bearing mice and control PMNs using the gene expression array described previously 17 . PMNMDSCs had a much higher expression of Slc27a2, which encodes FATP2. This was confirmed by quantitative PCR (qPCR) (Fig. 1a) . No upregulation of other transporters and receptors involved in lipid accumulation was detected (Extended Data Fig. 1h ). In contrast to PMNMDSCs, the expression of Slc27a2 was barely detectable in M-MDSCs from the same tumour-bearing mice (Fig. 1b) . Dendritic cells, spleen and tumour-associated macrophages had undetectable and CD8 + T cells had very low expression of Slc27a2 (Fig. 1c) . Increased amounts of FATP2 protein were confirmed by western blot in PMN-MDSCs isolated from the spleens of tumour-bearing mice (Extended Data Fig. 2a ) or generated in vitro with tumour explant supernatant (Extended Data  Fig. 2b) .
Next, we asked whether FATP2 might regulate the functionality of PMN-MDSCs. We analysed the function of PMN-MDSCs isolated from Slc27a2 −/− mice. These mice were originally generated on the SV129 background. Therefore, we established a syngeneic sarcoma (F244) in Slc27a2 −/− and wild-type mice. Tumours were spontaneously rejected in FATP2-knockout (Slc27a2 −/− ) mice (Extended Data  Fig. 2c ). Slc27a2 −/− mice were then backcrossed for ten generations to the C57BL/6 background. In these mice, the growth of LLC and EL4 tumours was markedly slower than in wild-type mice (Fig. 1d) . To test whether that effect was mediated by haematopoietic cells, we established bone marrow chimaeras by reconstituting lethally irradiated recipient congenic mice with bone marrow cells from wild-type or FATP2-knockout mice. Tumours established in mice reconstituted with FATP2-knockout bone marrow cells grew substantially slower than the tumours in mice reconstituted with wild-type bone marrow cells (Fig. 1e) . Depletion of CD8 + T cells from LLC or EL4 tumour-bearing mice completely abrogated the anti-tumour activity observed in FATP2-knockout mice (Fig. 1f) . To confirm whether FATP2 depletion in PMNs causes the observed anti-tumour effect, we generated conditional knockout Slc27a2 fl/fl mice and crossed them with S100a8-cre mice to target the deletion to PMNs (Extended Data Fig. 2d ). In the absence of FATP2 in PMNs, the tumours grew markedly slower than in control mice (Fig. 1g) . Loss of FATP2 did not affect the functionality of CD8 + T cells (Extended Data Fig. 2e ). Because the functionality of PMN-MDSCs depends on tumour burden, we compared PMN-MDSCs from wild-type and FATP2-knockout tumour-bearing mice depleted of CD8 T cells, which allows for the analysis of mice with the same tumour size. In both the spleens and tumours of FATP2-knockout mice, PMN-MDSCs lost the ability to suppress antigen-specific CD8 + T cell responses (Fig. 1h) . By contrast, the suppressive activity of M-MDSCs (Extended Data Fig. 2f ) or tumour-associated macrophages (Extended Data Fig. 2g ) was not affected.
Expression of Slc27a4 was slightly upregulated in PMN-MDSCs compared to control PMNs (Extended Data Fig. 1h ). However, in contrast to FATP2-knockout mice, no differences in tumour growth or suppressive function of PMN-MDSCs were found between wild-type and FATP4-knockout tumour-bearing mice (Extended Data Fig. 2h, i) . CD36 has been shown to affect lipid accumulation in different myeloid cells. Because tumours in CD36-knockout mice may grow slower than in wild-type mice and growth depends on CD8 T cells 12 , we analysed the lipid levels in PMN-MDSCs from CD36-knockout and wild-type mice after CD8 T cell depletion. We found no difference in lipid accumulation between knockout and wild-type PMN-MDSCs (Extended Data Fig. 2j, k) . 
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Whole-genome RNA sequencing (RNA-seq) analysis was performed on spleen PMN-MDSCs isolated from wild-type and FATP2-knockout tumour-bearing mice. Deletion of FATP2 resulted in significant changes in 1,119 genes (false discovery rate (FDR) <5%, at least twofold), with 37 genes showing marked changes of at least fivefold (Extended Data Fig. 3a) . There was an overall predominance of genes downregulated in FATP2-knockout mice (Extended Data Fig. 3b ). Enrichment analysis of significantly affected genes using ingenuity pathway analysis revealed that PMN-MDSCs from FATP2-knockout mice had a marked decrease in pro-inflammatory genes (Extended Data Fig. 3c ). −/− HPCs in the presence of arachidonic acid. Representative of two independent experiments. Dashed line shows T cell proliferation without MDSCs. Data are mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (between control and test samples), unpaired two-sided Student's t-test. a-f, The concentration is shown as pmol per mg of protein.
FATP2 regulates uptake of AA and PGE 2 synthesis
Article reSeArcH of LLC FATP2-knockout mice compared with PMN-MDSCs from wild-type mice, and particularly of triglycerides that contain arachidonic acid (20:4) (Fig. 2a) . Triglycerides containing other polyunsaturated fatty acids: linoleic acid (18:2), docosapentaenoic acid (22:5) and docosahexaenoic acid (22:6) were markedly reduced in PMN-MDSCs from FATP2-knockout mice (Extended Data Fig. 4a ). No differences in the total content of cholesterol esters or arachidonoyl-containing cholesterol esters were found (Extended Data Fig. 4b ). The content of free arachidonic acid was decreased (Fig. 2b) . The total content of phospholipids was not changed (Extended Data Fig. 4d ), whereas many molecular species of arachidonoyl-containing phospholipids were markedly reduced (Fig. 2c, Extended Data Fig. 4e ). Thus, genetic elimination of FATP2 caused selective depletion of arachidonoyl-containing species of phospholipids. These finding are consistent with the previous observation that although FATP2 is not a selective transporter for arachidonic acid, its overexpression favours increased uptake and trafficking of the fatty acid 16 . We next used a method of stable isotope labelling using deuterated arachidonic acid (AA-d 11 ) and high mass accuracy/high resolution LC-MS with tandem mass spectrometry (MS/MS) fragmentation analysis to trace directly the uptake of exogenously added AA-d 11 by PMN-MDSCs from wild-type and FATP2-knockout LLC tumour-bearing mice. We detected significantly lower amounts of AA-d 11 , as well as d 11 -labelled prostaglandin E 2 (PGE 2 ) in FATP2-knockout PMNMDSCs compared to wild-type cells (Fig. 2d) . We also observed a significant reduction of AA-d 11 -containing phospholipids ( Table 1 ). This was consistent with the markedly reduced amounts of the total (unlabelled) free arachidonic acid and its metabolite PGE 2 ( Fig. 2b) , as well as unlabelled arachidonoyl-containing phospholipids (Extended Data Fig. 4e ). No significant differences were observed in the total amounts of linoleic acid (18:2), docosapentaenoic acid (22:5), docosahexaenoic acid (22:6), palmitic acid (16:0), oleic acid (18:1) and α-linolenic acid (18:3) (Extended Data Fig. 4c and data not shown).
Next, we asked whether a lack of FATP2 affected the metabolic activity of PMN-MDSCs. Spleen PMN-MDSCs deficient in FATP2 did not show changes in oxidative phosphorylation (Extended Data Fig. 5a ) and glycolysis (Extended Data Fig. 5b ) compared to wild-type PMN-MDSCs. We studied fatty acid oxidation in more detail using the incorporation of 13 C 16 -palmitate to metabolites of the tricarboxylic acid cycle. No differences in labelled metabolites were found between wild-type and FATP2-knockout PMN-MDSCs (Extended Data Fig. 5c ). Neither splenic nor tumour PMN-MDSCs from FATP2-knockout mice showed changes in the expression of Cpt1a, Hadha or Acadm, major enzymes involved in fatty acid oxidation (Extended Data Fig. 5d ). There were also no differences in the uptake of the major nutrients between wild-type and FATP2-knockout PMN-MDSCs (Extended Data Fig. 6 ). Together, these data indicate that a lack of FATP2 does not affect fatty acid oxidation in PMN-MDSCs.
Arachidonic acid is a key precursor of PGE 2 , which was implicated in the suppressive activity of MDSCs in cancer [18] [19] [20] [21] and PMN-MDSCs from neonates 22 . We therefore sought to investigate whether FATP2 regulates the suppressive functions of PMN-MDSCs through the accumulation of arachidonic acid and the subsequent production and release of PGE 2 . Using LC-MS (Extended Data Fig. 7a ) and enzymelinked immunosorbent assay (ELISA) analysis (Extended Data Fig. 7b) , we confirmed that PMN-MDSCs produced and released significantly higher amounts of PGE 2 than control PMNs. This was associated with higher expression of Ptges, which encodes the prostaglandin E synthase enzyme (Extended Data Fig. 7c ). PMN-MDSCs from FATP2-knockout tumour-bearing mice release significantly less PGE 2 than wild-type PMN-MDSCs (Fig. 2f) . This was consistent with significantly lower amounts of intracellular PGE 2 in FATP2-deficient PMNMDSCs than in wild-type cells (Extended Data Fig. 7b ). Consistent with a reduced amount of substrate, the expression of the Ptgs2 and Ptges genes involved in PGE 2 synthesis was lower in FATP2-knockout PMN-MDSCs than in wild-type PMN-MDSCs (Extended Data  Fig. 7d ). There was no difference in the expression of the Arg1 and Nos2 genes commonly associated with MDSC activity between wildtype and knockout PMN-MDSCs (Extended Data Fig. 7e ). We transduced HPCs with lentivirus expressing Slc27a2-gfp or control lentivirus and differentiated these to PMNs in the presence of granulocytemacrophage colony-stimulating factor (GM-CSF). Overexpression of Slc27a2 (Fig. 2g ) resulted in increased production of PGE 2 in GFP + PMNs compared to GFP − PMNs (Fig. 2h ). To test whether arachidonic acid could drive the accumulation of suppressive PMNs, we generated PMNs from HPCs in the presence of GM-CSF and arachidonic acid and found that the addition of fl/fl × S100a8-cre) mice treated with GM-CSF. Representative of three experiments. d, Lipid accumulation (determined by BODIPY staining) in PMN-MDSCs isolated from the blood of healthy individuals (n = 9) or patients with head and neck cancer (n = 11), non-small-cell lung cancer (n = 6) or breast cancer (n = 5). MFI, mean fluorescence intensity. e, Lipid accumulation (BODIPY staining) in PMN-MDSCs isolated from blood and tumour tissue of patients with non-small-cell lung cancer (n = 4). f, Expression of SLC27A2 (determined by RT-qPCR) in PMN-MDSCs isolated from the blood of patients with cancer or in PMNs of healthy donors. Fold change compared with control PMNs (n = 6). g, FATP2 protein in PMN-MDSCs isolated from the blood of patients with cancer or in PMNs of healthy individuals. Representative of three experiments. h, SLC27A2 (RT-qPCR) in LOX1
+ and LOX1 − PMNs from the blood of patients with cancer. Fold change compared with LOX1 − PMNs (n = 8). i, LS-MS lipidomics analysis of triglycerides in PMNs from healthy donors and PMN-MDSCs from patients with cancer. n = 4. j, LS-MS lipidomics analysis of free arachidonic acid, linoleic acid (LA) and docosahexaenoic (DHA) in PMNs from healthy donors and in PMN-MDSCs from patients with cancer (n = 4). k, LS-MS lipidomics analysis of PGE 2 in PMNs from healthy donors and in PMN-MDSCs from patients with cancer (n = 4). Data are mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, twoway ANOVA (d) or unpaired two-sided Student's t-test (e, f, h-k). i-k, The concentration is shown as pmol per mg of protein. . 7f ) that suppressed antigen-specific T cell responses (Fig. 2i ). This suppressive activity was associated with a higher production of PGE 2 ( Fig. 2j) , increased expression of Nox2, but not Arg1 or Nos2 (Extended data Fig. 7g ). To verify the specific role of PGE 2 in arachidonoyl-inducible suppressive activity of neutrophils, we generated PMNs from COX2-deficient (Ptgs2
) HPCs. In the absence of COX2, synthesis of PGE 2 was decreased (Fig. 2k) . The presence of arachidonic acid during PMN differentiation from Ptgs2 −/− HPCs was not able to generate suppressive PMN-MDSCs (Fig. 2l) . Together, these data suggested that FATP2 controls the suppressive activity of PMN-MDSC via increased uptake of arachidonic acid and synthesis of PGE 2 .
The Slc27a2 promoter has a binding site for the transcription factor STAT5 (http://jaspar.genereg.net/). STAT5 can be activated by GM-CSF, which has a crucial role in myelopoiesis and the expansion of MDSCs 23 .
To explore whether GM-CSF might control Slc27a2 expression through STAT5 activation, we treated PMNs isolated from the bone marrow of tumour-free mice with GM-CSF for 2 h. As expected, it caused a dose-dependent activation of STAT5 (determined by STAT5 phosphorylation) (Extended Data Fig. 7h ). This activation was associated with the upregulation of FATP2 (Fig. 3a) . Chromatin immunoprecipitation (ChIP) experiments demonstrated that STAT5 could directly bind to the Slc27a2 promoter (Fig. 3b) . Conversely, GM-CSF failed to increase the expression of FATP2 in STAT5-deficient PMNs (Fig. 3c) .
To confirm the role of STAT5 in controlling the expression of Slc27a2 in PMNs, we crossed Stat5 fl/fl mice with S100a8-cre mice to target the deletion of STAT5 to PMNs. In the absence of STAT5 in PMNs, tumour growth was slower than in control mice (Extended Data Fig. 7i ). This was associated with lower expression of Slc27a2 in PMNs (Extended Data Fig. 7j ). These data indicate that GM-CSF regulates the expression of Slc27a2 through the activation of phosphorylated STAT5 (pSTAT5).
Increased lipids and FATP2 in human PMN-MDSCs
PMN-MDSCs isolated from the blood of patients with head and neck, lung or breast cancer accumulated more lipids than PMNs from healthy donors (Fig. 3d) . PMN-MDSCs in tumours had higher amounts of lipids than PMN-MDSCs in the blood of the same patients (Fig. 3e) . PMN-MDSCs from patients with cancer had higher expression of SLC27A2 (Fig. 3f) and FATP2 (Fig. 3g) than control PMNs. M-MDSCs isolated from the blood of patients with cancer also had more lipids than monocytes from healthy donors (Extended Data  Fig. 8a ). However, there was no difference in the accumulation of lipids in M-MDSCs isolated from the blood or tumours of the same patient (Extended Data Fig. 8b) . Recently, we identified LOX1 as a marker of human PMN-MDSCs 24 . Analysis of a gene expression array 24 revealed that LOX1
+ PMN-MDSCs had higher expression of SLC27A2 but not of other transporters as compared with LOX1 − PMNs from the same patients (Extended Data Fig. 8c ). The higher expression of SLC27A2 in LOX1
+ PMN-MDSCs was validated by reverse transcription qPCR (RT-qPCR) (Fig. 3h) . SLC27A2 expression was associated with higher expression of PTGES (Extended Data Fig. 8d ). By contrast, M-MDSCs had lower expression of SLC27A2 than monocytes (Extended Data  Fig. 8e ). Similar to the results obtained in mice, GM-CSF upregulated pSTAT5 (Extended Data Fig. 8f ) and FATP2 (Extended Data Fig. 8g) .
Using LS-MS lipidomics analysis, we identified a substantially higher amount of total triglycerides (Fig. 3i) and free arachidonic acid, linoleic acid and docosahexaenoic acid (Fig. 3j ) in PMN-MDSCs from patients with cancer than in PMNs from healthy individuals. Higher amounts of PGE 2 were detected in PMN-MDSCs than in control PMNs (Fig. 3k) . The contents of total phosphatidylethanolamine and arachidonoyl-containing phosphatidylethanolamine were increased in PMN-MDSCs from patients with cancer compared with PMNs from healthy donors (Extended Data  Fig. 8h) . Thus, clinical data recapitulated the observations in mice.
Therapeutic targeting of FATP2
Next, we sought to determine the effect of pharmacological inhibition of FATP2 on tumour growth. To inhibit FATP2 in tumour-bearing mice, we used the selective FATP2 inhibitor lipofermata (5-bromo-5′-phenylspiro[3H-1,3,4-thiadiazole-2,3′-indoline]-2-one) 15, 25 . Lipofermata at the range of concentrations corresponding to the dose used in vivo (0.2 mg ml −1 ) did not affect the proliferation of EL4 and LLC tumour cells in vitro (Extended Data Fig. 9a ). In four tested tumour models, lipofermata caused a significant delay in tumour growth (Fig. 4a) . Notably, this effect was absent in immunodeficient non-obese diabetic-severe combined immunodeficiency (NOD/SCID) mice (Fig. 4b) , and depletion of CD8 + T cells in immunocompetent mice abrogated the effect of lipofermata (Fig. 4c) . These data indicate that the antitumour effect of FATP2 inhibition was mediated via immune mechanisms. In the TC-1 mouse tumour model, treatment with lipofermata increased the percentage and absolute numbers of antigen-specific T cells in draining lymph nodes (Extended Data Fig. 9b) .
We asked whether lipofermata could provide additional therapeutic benefit if combined with checkpoint inhibitors. Treatment of LLCbearing mice with lipofermata or CTLA4 alone had an antitumour effect. However, neither treatment option blocked tumour progression. By contrast, the combination of anti-CTLA4 antibody and lipofermata caused a potent antitumour effect, with four out of five mice rejecting tumours (Fig. 4d) . A similar combination effect was observed in the TC-1 model (Extended Data Fig. 9c ). The antitumour effect was associated with a substantial infiltration of CD8 + T cells of tumours in treated mice (Extended Data Fig. 9d) . A combination of anti-PD1 antibody and lipofermata in the TC-1 model also resulted in a significant decrease in tumour growth, although this effect was less pronounced . e, Growth of LLC tumours in mice treated with CSF1R inhibitor and lipofermata (n = 5). Data are mean ± se.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (differences from untreated cells and between treated groups), two-way ANOVA with corrections for multiple comparison. NS, not significant. Data Fig. 9e ). Because FATP2 is overexpressed only in PMNMDSCs, we asked whether the antitumour effects of lipofermata could be potentiated by combining with the inhibition of tumour-associated macrophages using an anti-CSF1R antibody. Consistent with previous observations 26 , inhibition of CSF1R alone had no effect on tumour growth in the LLC tumour model. However, the combination of lipofermata and CSF1R inhibition resulted in an antitumour effect (Fig. 4e) .
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Our study has identified FATP2 as a crucial regulator of the immunosuppressive function of PMN-MDSCs, and FATP2 mediates its effect via regulation of the accumulation of arachidonic acid and subsequent synthesis of PGE 2 . These findings are consistent with results that demonstrate that the production of PGE 2 supports tumour growth and immune escape 27 . Our study suggests the possibility of highly selective targeting of MDSCs in cancer. Previous reports established the potential role of COX2 inhibitors in blockade of MDSC expansion in mouse tumour models 18, 22, 28, 29 . However, prolonged systemic use of COX2 inhibitors is associated with substantial haematological, cardiovascular and gastrointestinal toxicities. Selective targeting of FATP2 in PMNMDSCs offers the opportunity to inhibit PGE 2 only in pathologically activated neutrophils and mostly within the tumour site, where the expression of FATP2 is highest. It is also possible that blockade of local release of PGE 2 at the contact between PMN-MDSCs and T cells in peripheral lymphoid organs can improve immune responses without resulting in any systemic effects of PGE 2 inhibition.
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MEthodS
Human samples. Samples of peripheral blood and tumour tissues were collected from patients at Helen F. Graham Cancer Center and University of Pennsylvania. The study was approved by Institutional Review Boards of the Christiana Care Health System at the Helen F. Graham Cancer Center, and The Wistar Institutional Review Board. All patients signed consent forms that were approved by the Institutional Review Board. Samples were collected at Helen F. Graham Cancer Center from 6 patients with previously untreated stage II-IV non-small-cell lung cancer, 11 patients with stage III-IV head and neck cancer, and 5 patients with stage III-IV breast cancer. This cohort includes 12 females and 10 males, aged 48-74 years. Peripheral blood was also collected from 9 healthy volunteers after obtaining informed consent. 
Slc27a4
fl/fl mice were obtained from W. Stremmel and crossed with B6.CgTg(S100A8-cre,-EGFP)1Ilw/J (Jackson Laboratory). In mouse tumour models, maximal tumour size approved by the IACUC was 2 cm in diameter. In none of the experiments was these limits exceeded. Sample size calculation was performed in advance. Studies were not blinded. In treatment experiments, mice were randomized before the start of therapy to different groups based on equal tumour size. Generation of PMN-specific Slc27a2-deficient mice. Mice were generated at CRISPR/Cas9 Mouse Targeting Core of University of Pennsylvania, using the CRISPR-Cas9 system as described 30 . Conditional knockout mice (Slc27a2 fl/fl ) were generated using the CRISPR-Cas9 genome-editing system, at CRISPR Cas9 Mouse Targeting Core of University of Pennsylvania by flanking exon 1 with loxP sites, as previously described 30 . The sequences for the guide RNAs (gRNAs) and repair templates used are as follows: Slc27a2 5′gRNA: GTCCACAATACCGTCGATGT GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAA CTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTT. Slc27a2 3′ gRNA: ACT CCTCCGTTATATGATTGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAA GGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTT TT. Slc27a2 5′ loxP oligoDNA:TTTACTTTGTTTGCTTTGTGTGTT TTGGTAAATGTCGAACTGAGTCCA CAATACCGTCGATGTataacttcgtataatgta tgctatacgaagttatTGGAAAGTGGCTCGCGTAACAGAACAAAATCTCAAAACA AATTAACAGGACCCCATTGCTCGA. Slc27a2 3′ loxP oligoDNA: ATACT GTAATGGATGGTTTTAATATTCTGATAAATTAAAAATCACTCCTCCGTT ATATGATTGataacttcgtataatgtatgctatacgaagttatAGGAAACATATAGAATTTTCC AGCCTAGCTCCGTCTTC AAAGCCCACGTTTCTTATACAGTGC. Lowercase bases indicate the 5′ and 3′ loxP sites. Slc27a2 fl/fl mice were then crossed with B6.Cg-Tg(S100A8-cre,-EGFP)1Ilw/J mice (Jackson Laboratory) to obtain mice with targeted deletion of FATP2. Reagents and cell lines. Tumour cell lines: EL4 (lymphoma), LLC (Lewis lung carcinoma), CT26 (colon carcinoma), TC-1 (HPV16 E6/E7-expressing tumour cell line) were obtained from the ATCC, and F244 (sarcoma) was provided by R. Schreiber. All cells were maintained in DMEM medium supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich) at 37 °C, 5% CO 2 . Tumour cells were injected subcutaneously 5 × 10 5 cells per mouse. Tumour cell lines were obtained from the ATCC and were tested for mycoplasma contamination by using the Universal Mycoplasma Detection kit (ATCC) every 3 months. SIINFEKL and EGSRNQDWL peptides were obtained from American Peptide Company. All reagents and antibodies used in the study are described in Supplementary Table 1 . Preparation of tumour explant supernatants. Tumour explant supernatants were prepared from excised non-ulcerated EL4 tumours approximately 1.5 cm in diameter. A small tumour piece (5-10 mm 2 ) was obtained, minced into pieces less than 3 mm in diameter and resuspended in complete RPMI without extra cytokines. After 16-18 h of incubation at 37 °C with 5% CO 2 , the cell-free supernatant was collected using 0.22-µm filters (EMD Millipore) and kept at −80 °C. Cell phenotype and lipid content by flow cytometry and confocal microscopy. Cells were incubated with FC-block (BD Biosciences) for 10 min and surface staining was performed at 4 °C for 15 min. Cells were run on LSRII flow cytometer (BD Biosciences) and data were analysed by FlowJo (Tristar). For lipid staining by flow cytometry, cells were re-suspended in 500 µl of BODIPY 493/503 at 0.25 µg ml −1 in PBS. Cells were stained for 15 min at room temperature in the dark, then washed twi ce, re-suspended in PBS and run immediately on LSRII. For lipid staining by confocal microscopy, cells were washed twice with PBS, resuspended in complete RPMI and 50,000 cells were seeded on poly-l-lysine-coated 12-mm round coverslips (Corning) for 45 min at 37 °C. Cells were fixed and permeabilized with Fixation & Permeabilization Buffers (BD Biosciences) for 15 min at room temperature, washed twice with wash buffer (BD Biosciences) and then stained with BODIPY for 15 min at room temperature. Cells were washed and incubated with DAPI and mounted on slides using ProLong Gold antifade reagent (Life Technology). The cells were imaged with a Leica TCS SP5 laser scanning confocal microscope (Leica Microsystems). Isolation of mouse cells. Single-cell suspensions were prepared from spleen and followed by red blood cell removal using ammonium chloride lysis buffer. Single-cell suspensions from tumour tissues were prepared using Mouse Tumour Dissociation Kit according to the manufacturer's recommendation (Miltenyi). CD8 + T cells were isolated from spleen and lymph nodes by using EasySep Mouse CD8 + T Cell Enrichment Kit (STEMCELL), following manufacturer's instructions. Suppression assay. Single-cell suspensions from spleen and tumours were prepared as described above. Then cells were stained and sorted on BD FACS Aria BD (Biosciences). PMN-MDSCs (CD45 /Mg 2+ and 20 mM EDTA (Invitrogen) was added 5 min at room temperature to stop the reaction. CD8 T cells were isolated from lymph nodes of tumour-bearing mice using EasySep Mouse CD8 + T Cell Enrichment Kit (STEMCELL) and stimulated with anti-CD3 and anti-CD28 antibodies (BD Biosciences) for 24 h and IFNγ was analysed by ELISpot (Mabtech), accordingly to the manufacturer's instructions. T cell proliferation was evaluated by flow cytometry using CSFE (BioLegend). Antigen-specific CD8 T cell responses were evaluated in single-cell suspensions obtained from lymph nodes of TC-1 (HPV16 E6/E7-expressing tumour cells) tumour-bearing mice by flow cytometry using the MHC tetramer (H-2Db HPV 16 E7, RAHYNIVTF), obtained from D. Weiner. Isolation of human cells. PMN-MDSCs and PMNs were isolated by centrifugation over a double-density gradient Histopaque (Sigma) (1.077 to collect peripheral blood mononuclear cells and 1.119 to collect PMNs) followed by labelling with phycoerythrin-conjugated CD15 antibody (CD15-PE) monoclonal antibody (BD Biosciences) and then separated using anti-phycoerythrin beads and MACS column (Miltenyi). Tissues were first digested with the human tumour dissociation kit (Miltenyi) and then red blood cells were lysed. Cells were then culture in RPMI (Biosource International) supplemented with 10% FBS, 5 mM glutamine, 25 mM HEPES, 50 µM β-mercaptoethanol and 1% antibiotics (Invitrogen). For isolation of LOX1 + PMNs from peripheral blood, whole blood was enriched for PMNs using the MACSxpress Neutrophil Isolation Kit (Miltenyi) following the manufacturer's protocol. Cells were then labelled with anti-LOX1-phycoerythrin monoclonal antibody (Biolegend) and then separated using anti-phycoerythrin beads and MACS column (Miltenyi). RT-qPCR. RNA was extracted using the Total RNA Kit according to the manufacturer's instructions. DNase digestion was performed cDNA was generated with HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems). RT-qPCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems) in 96-or 384-well plates. Plates were read with ABI 7900 (Applied Biosystems). Amplifications were carried out with the primers described in Supplementary Table 2 . RNA-seq. RNA-seq data were aligned using bowtie2 31 against mm10 version of the mouse genome and RSEM v1.2.12 software 32 was used to estimate raw read counts using Ensemble v84 gene information. DESeq2 33 was used to estimate significance of differential expression between sample groups. Overall gene expression changes were considered significant if they passed the false discovery rate (FDR) <5% threshold. Significant genes affected by at least twofold were analysed for enrichment of upstream regulators using QIAGEN's Ingenuity Pathway Analysis software (IPA, QIAGEN, www.qiagen.com/ingenuity, 'upstream analysis' option). Only regulators with significantly enriched P < 0.005 targets (at least 20) with significantly predicted activation state (activation z score |Z| > 2) were considered. Western blot. Cells were lysed in RIPA buffer (Sigma-Aldrich) in the presence of protease inhibitor cocktail (Sigma-Aldrich), sonicated and stored at −80 °C. Whole-cell lysates were prepared and subjected to 10% SDS-PAGE and transferred to PVDF membrane. The membranes were probed overnight at 4 °C with antibodies specific for FATP2 (SLC27A2) (ThermoFisher), β-actin, GAPDH or STAT5 (Cell Signaling Technology). Membranes were washed and incubated for 1 h at room temperature with secondary antibody conjugated with peroxidase. Generation of suppressive neutrophils in vitro. Mouse neutrophils were generated from enriched bone marrow HPCs with 20 ng ml −1 GM-CSF. In brief,
Article reSeArcH
HPCs were isolated from mouse bone marrow using the Lineage Cell Depletion Kit (Miltenyi), according to the manufacturer's instructions. Cells were seeded at 25,000 cells per ml in 24-well plates, and GM-CSF (20 ng ml −1 ) and 20% (v/v) tumour explant supernatant or arachidonic acid (10 µM) were added at days 0 and 3. At day 5, Ly6G-positive neutrophils were isolated using anti-Ly6G biotin (Miltenyi) and streptavidin beads (Miltenyi), according to the manufacturer's instructions. FATP2 overexpression in HPCs and PGE 2 ELISA. HPCs were isolated from mouse bone marrow using the Lineage Cell Depletion Kit (Miltenyi), according to the manufacturer's instructions. HPCs were resuspended in serum-free medium containing lentiviral vectors followed by centrifugation of the plate at 1,000 r.p.m. for 20 min at 25 °C. Fresh medium supplemented with GM-CSF (20 ng ml −1 ) was then added and cells were seeded at 25,000 cells per ml in 24-well plates. At day 3, GM-CSF and 20% (v/v) tumour explant supernatant were added to the culture. At day 5, cells were collected, stained with phycoerythrin-conjugated anti-mouse Ly6G, allophycocyanin (APC)-conjugated anti-mouse Ly6C and BV42-conjugated anti-mouse CD11b, and GFP − and GFP + Ly6G + cells were sorted on BD FACS Melody (BD Biosciences). GFP − and GFP + Ly6G + cells were seeded at 2,000,000 cells per ml in the presence of GM-CSF and tumour explant supernatant and incubated for a further 24 h. Pellets and supernatants were collected for further analysis. PGE 2 concentration in supernatants was measured by using the PGE 2 ELISA Kit (Invitrogen), according to manufacturer's instructions. Uptake and tracing of arachidonic acid. Splenic PMN-MDSCs from wild-type and Slc27a2
−/− LLC tumour-bearing mice were cultured in complete medium (RPMI plus 10% FBS) with 100 nM of AA-d 11 (Cayman Chemicals), conjugated to 10% fatty acid-free BSA (Sigma Aldrich), and 10 ng ml −1 GM-CSF. After 16-18 h, supernatants and cellular pellets were collected and stored at −80 °C. Lipids (including PGE 2 and PGE 2 -d 11 ) were analysed by LC-MS; the amounts of PGE 2 in the supernatants were measured by ELISA. Immunofluorescence microscopy. Immunofluorescence staining of CD8 was performed on frozen mouse tumour tissue sections. Rat monoclonal anti-mouse CD8a primary antibody (BD Pharmingen) and Alexa Fluor 594 goat anti-rat IgG (H+L) secondary antibody (Invitrogen) were used for the staining. Cell nuclei were stained with DAPI. Imaging was performed using a Leica TCS SP5 confocal microscope. Sixteen frames acquired with a 63× objective lens were used to calculate the cell number per mm 2 . Seahorse analysis. Metabolic rates were determined using the Seahorse XFe24 and XFe96 Flux Analyzers (Agilent Technologies) following the manufacturer's protocol. In brief, the microplate was coated with 22.4 µg ml −1 Cell-Tak (Fisher) using 200 mM sodium bicarbonate. Approximately 400,000 cells were seeded per well immediately after isolation in 50 µl and 80 µl of unbuffered RPMI (Sigma-Aldrich) for the XF24 and XF96 analysers, respectively. The microplate was incubated for 30 min at 37 °C to allow the cells to settle into a monolayer. Unbuffered RPMI was gently added to the wells without disturbing the monolayer to bring the assay volume to 675 µl and 180 µl for the XFe24 and XFe96 analysers, respectively. The basal oxygen consumption rate and extracellular acidification rate were measured, in addition to rate changes after treatment with 5 µM oligomycin (SigmaAldrich), 1 µM FCCP (Sigma-Aldrich), and 0.75 µM rotenone and 1 µM antimycin A (Sigma-Aldrich). Chromatin immunoprecipitation. ChIP assays were performed as described previously 34 . In brief, peripheral blood mononuclear cells were treated with or without GM-CSF (10 ng ml −1 and 100 ng ml
) for 20 min. Cells were then fixed in 1% formaldehyde for 10 min. DNA was sonicated to obtain 200-400-bp DNA fragments on a Diagenode Bioruptor according to the manufacturer's protocol. The following antibodies were used for ChIP assays: anti-rabbit IgG (Santa Cruz Biotechnology), anti-phospho-STAT5 alpha (Tyr694) antibody (6H5L15) rabbit monoclonal (Invitrogen). Primers for the ChIP assays are listed in Supplementary  Table 2 . PCR data were normalized to input values that were quantified in parallel for each experiment. Tumour cell injections and treatment. Approximately 5 × 10 5 tumour cells were injected subcutaneously into mice, which formed tumours with a 1.5-cm diameter within 2-3 weeks of injection. Lipofermata was administrated subcutaneously at a dose of 2 mg kg −1 twice a day. As a control, mice were treated with vehicle alone (DMSO plus 30% (v/v) Kolliphor). Treatments with lipofermata started 8-10 days after tumour injections. CSF1R antibody (BioXcell, 300 µg per mouse) was administered every other day starting the day after tumour injection, and continued until the mice were euthanized. PD-1 antibody (clone RMP1-14, BioXcell, 200 µg per mouse) was administered twice a week started 10-12 days after tumour injection. CTLA4-IgG2a (BioXcell, 200 µg per mouse) was administered at days 7 and 11. LC-MS of lipids. Lipids were extracted by Folch procedure with slight modifications, under nitrogen atmosphere at all steps. The detailed protocol is provided in the Supplementary Information. Liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) analysis of lipids was performed on a Dionex HPLC system (using the Chromeleon software), consisting of a Dionex UltiMate 3000 mobile phase pump, equipped with an UltiMate 3000 degassing unit and UltiMate 3000 autosampler (sampler chamber temperature was set at 4 °C). The Dionex HPLC system was coupled to an Orbitrap Fusion Lumos mass spectrometer (ThermoFisher Scientific) or to a hybrid quadrupole-orbitrap mass spectrometer, Q-Exactive (ThermoFisher Scientific) with the Xcalibur operating system. The instrument was operated in negative and positive ion modes (at a voltage differential of −3.5-5.0 kV, source temperature was maintained at 150 °C). Phospholipid mass spectrometry (MS) and tandem mass spectrometry (MS/MS) analyses were performed on an Orbitrap Fusion Lumos mass spectrometer (see Supplementary Information). MS and MS/MS analysis of free fatty acids, triglycerides and cholesterol esters were performed on a Q-Exactive hybrid-quadrupole-orbitrap mass spectrometer (ThermoFisher Scientific) (see Supplementary  Information) . MS lipid standards were from Avanti Polar Lipids and Cayman Chemical Company. Analysis of LC-MS data was performed using the software package Compound Discoverer (ThemoFisher Scientific). Construction of the LV-GFP-Slc27a2 plasmid. The Slc27a2 gene was amplified from the pCMV6-Kan/Neo-Slc27a2 plasmid (Origene, MC206275) using the following primers: Slc27a2_For_X maI (GGTGGTCCCGGGCCTATGCTGCCAGTGCTCTACAC) and Slc27a2_Rev_ SalI (GGTGGTGTCGACTCAGAGCTTCAGAGTTTTAT). The amplified PCR product was then digested with XmaI/SalI and cloned into a SIV-based self-inactivating lentiviral transfer vector downstream of GFP (pGAE-CMV-GFP-P2A-Slc27a2-Wpre). The transfer vector pGAE-CMV-GFP-Wpre, the packaging plasmid pAd-SIV3+, and the vesicular stomatitis virus envelope G protein (VSV-G) pseudotyping vector from Indiana serotype (pVSV.G IND ) have been previously described 35, 36 . Vector production and validation is described in the Supplementary Information. Statistical analysis. Statistical analysis was performed using an unpaired two-tailed Student's t-test with significance determined at P = 0.05. Estimation of variation within each group of data was performed and variance was similar between groups that were compared. Animal experiments were not blinded. Tumour growth was evaluated using a two-way ANOVA test with Bonferroni correction for multiple comparisons. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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